Inovio Pharmaceuticals (INO) Fundamental Analysis: Revenue, Earnings & Valuation

5.50 / 10

Netural

Fundamentally INO scores 5.5/10, reflecting modest strength. Revenue‑MV and Cash‑MV are above peers, while Fixed‑asset turnover and Income‑tax‑to‑profit ratios lag. YoY revenue fell ~70%, limiting growth prospects. Overall the fundamentals are neutral to slightly bearish.

Analysis Checks(7/10)

Revenue-MV

Value-0.11

Score2/3

Weight17.83%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value-69.99

Score3/3

Weight2.83%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight14.54%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.31%

1M Return1.69%

PB-ROE

Value-0.21

Score1/3

Weight12.18%

1M Return5.29%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-0.84%

1M Return-0.50%

Fixed assets turnover ratio

Value0.01

Score1/3

Weight-2.03%

1M Return-1.24%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight8.41%

1M Return4.32%

Asset-MV

Value-0.55

Score3/3

Weight30.85%

1M Return11.84%

Cash-MV

Value0.02

Score2/3

Weight12.91%

1M Return5.94%

Is INO fundamentally strong?

INO scores 5.50/10 on fundamentals and holds a Fair valuation at present. Backed by its -183.47% ROE, -130000.00% net margin, -1.42 P/E ratio, 4.99 P/B ratio, and 54.18% earnings growth, these metrics solidify its Netural investment rating.